"The last several years have been particularly exciting in the area of metastatic castrate-resistant prostate cancer," writes J. Brantley Thrasher, MD.
J. Brantley Thrasher, MD
In this interview, Mark Frydenberg, MD, discusses the evolution of PET scanning, its clinical indications, its advantages and drawbacks, and key questions that remain about its use.
In this interview, Jim Kovarik, PA-C, discusses the role of advanced-practice providers in a urology practice, how they are trained, and what procedures they can and should perform.
AI is poised to revolutionize use of medical data, but challenges remain.
In this interview, John W. Davis, MD, discusses the advantages and limitations of focal therapy, the ideal candidate, and what current guidelines say about its use.
“Active surveillance continues to gain traction as a management strategy for low-risk prostate cancer in the United States. However, barriers still exist and challenges remain for both the treating urologist and the patient,” writes J. Brantley Thrasher, MD.
In this interview, E. Jason Abel, MD, discusses biopsy’s role in small and large renal masses, associated risks, and when patients can be safely observed.
In this interview, Arie Belldegrun, MD, discusses the benefits of cancer immunotherapy, the importance of a multidisciplinary treatment approach, and what the future holds for this treatment.
The AUA is challenged with staying fair and relevant to all urologists under the "big tent," even though academic-employed urologists, non-academic-employed urologists, those in private practice, and those in large group practices may have different priorities and problems.
PSA is performing appropriately, allowing us to diagnose prostate cancers at an earlier stage and grade and allowing treatment while cure is still possible.